To mitigate the risks associated with failure to warn, companies should:
Conduct thorough risk assessments and safety testing of their nanotechnology products. Stay updated with the latest research and regulatory guidelines. Provide clear, comprehensive, and accessible safety information to consumers and other stakeholders. Implement robust monitoring and reporting mechanisms for adverse effects.
